Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)
Additional areas of investigation Researchers are also studying semaglutide in obstructive sleep apnea (where weight loss significantly improves symptoms), heart failure with preserved ejection fraction (HFpEF), peripheral artery disease, polycystic ovary syndrome, and even addiction disorders
When prescribing or taking both omeprazole and semaglutide concurrently, several clinical considerations warrant attention to optimise therapeutic outcomes and minimise potential complications
In recent years, it has also gained approval for weight loss treatment, particularly in people who struggle with obesity or those at risk for heart disease due to being overweight
In the brain, it acts on appetite centers in the hypothalamus, directly reducing hunger signals and food cravings
So-called non-responders are people who lose less than 5% of their body weight after roughly six months of treatment on the highest tolerated dose
